Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp508 | Paediatric bone disease | ECTS2013

Comparison of the bone densitometry and anthropometric parameters between the Ukrainian, Indian and Nigerian young male students, graduated in Lugansk State Medical University

Luzin V , Stklyanina L , Ushko Y , Ignatyev A

Objectives: To establish the average bone mineral density (BMD) and bone mineral content (BMC) in young male population from the different ethno-geographical groupsMaterials and methods: Estimations of the calcaneal BMD (g/cm2) and BMC (r), using on ALOKA-5.0 DXA machine among Indian (n=58) and Nigerian (n=72) male students (17–20 years), were done. The anthropometric program included body weight, height, shoulder and th...

ba0001pp394 | Osteoporosis: treatment | ECTS2013

Effects of a new conjugate drug in a rat model of postmenopausal osteoporosis

Liu Careesa , Young Robert , Grynpas Marc

Introduction: Standard clinical treatments for postmenopausal osteoporosis utilize resorption-inhibiting drugs such as bisphosphonates, which selectively bind to bone mineral but also suppress bone formation over time. Prostaglandin E2 (PGE2) has bone-anabolic effects in vivo, but its clinical utility is hindered by side effects upon systemic administration. Since PGE2 acts on bone via the EP4 receptor, our approach utilizes a specific...

ba0001pp418 | Osteoporosis: treatment | ECTS2013

Myricetin suppress LPS-induced MMP expression in human periodontal ligament fibroblasts and inhibit osteoclastogenesis by downregulating NFATc1 in LPS-induced RAW 264.7 cells

Ko Seon-Yle , Jang Young-Joo

Periodontitis is an inflammatory disease that affects connective tissue attachments and the supporting bone that surrounds the teeth. Periodontal ligament fibroblasts induce the overexpression of matrix metalloproteinase (MMP), which is involved in inflammatory progression in periodontitis. Osteoclasts are responsible for skeletal modeling and remodeling but may also destroy bone in several bone diseases, including osteoporosis and periodontitis. This study examined the anti-d...

ba0005p67 | Bone development/growth and fracture repair | ECTS2016

Comparison of osteoconductivity and absorbability of beta-tricalcium phosphate and hydroxyapatite in open wedge high tibial osteotomy

Oh Kwang Jun , Koh Young Bong

The purposes of this present study were to compare the osteoconductivity and absorbability in patients of open wedge high tibial osteotomy with medially gaps filled with hydroxyapatite (HA) or beta-tricalcium phosphate (β-TCP).Total 41 knees of 40 patients in whose follow up period more than 1 year were enrolled. The patients were divides into two groups, group I (22 knees, 21 patients) used HA and group II (19knees, 19 patients) used β-TCP...

ba0007p130 | (1) | ICCBH2019

Off label uses of pamidronate in rare pediatric bone diseases (Jansen's Metaphyseal Chondrodysplasia and Generalized Arterial Calcification of Infancy): A four year perspective

Young Kyleen , Langman Craig , Jueppner Harald

Background: Pamidronate is FDA approved only in adults. It is frequently used off-label in the treatment of pediatric bone diseases, such as osteogenesis imperfecta, juvenile osteoporosis, and osteopenia in nonambulatory patients with cerebral palsy. The use of pamidronate in these conditions is relatively common, but there may be more to be understood about its role in other rare pediatric bone diseases.Presenting problem: Jansen’s Metaphyseal Chon...

ba0005p385 | Osteoporosis: treatment | ECTS2016

The effect of teriparatide on fracture healing of vertevral compression fracture in postmenopausal women

Young Park Si , Woo Suh Seung , Young Hong Jae , Rae Kim Jung

Introduction: Acute vertebral compression fractures cause severe back pain and need long time to heal. The progression of fracture or nonunion is not rare. The teriparatide is a synthetic parathyroid hormone which has been used as anabolic agent and treatment of osteoporosis. It can also be used for promoting fracture healing in special condition. Periodic infusion of teriparatide enhances bone formation and increases bone strength. We evaluated the effect of periodic teripara...

ba0001pp420 | Osteoporosis: treatment | ECTS2013

Subsequent hip fracture in Inchon and Bucheon area of Korea (Cohort study)

Moon Kyoung Ho , Kim Ju Young , Lee Kee Haeng

Introduction: A significant number of patient who have experienced previous surgical treatment for an osteoporotic hip fracture, experienced a subsequent hip fracture (SHF) on the opposite side. The incidence of asynchronous bilateral hip fractures is 1.7–14.8%. All hip fracture patients treated at five university hospitals in the Inchon and Bucheon area of Korea, were reviewed. The patients were divided into two groups, a group that had experienced subsequent hip fractur...

ba0003pp163 | Cell biology: osteoclasts and bone resorption | ECTS2014

The molecular mechanism of n-butanol extracts of Panax notoginseng on RANKL-induced osteoclastogenesis in RAW264.7 cells

Hwang Hyo-In , Jang Young-Joo , Ko Seon-Yle

This study examined the anti-osteoclastogenic effect of n-butanol extracts of Panax notoginseng on the receptor activator of NF-kB ligand (RANKL) induced RAW264.7 cells. Panax notoginseng is commonly used to treat chronic liver disease. Notoginseng has many beneficial effects, such as the suppression of liver fibrosis and anti-cancer activities. Notoginseng contains several biologically active components, such as ginsenosides Rb1, Rg1...

ba0003pp171 | Cell biology: osteoclasts and bone resorption | ECTS2014

The purinergenic receptor P2Y14 is essential for RANKL-induced osteoclastogenesis

Park Jin Hee , Jung Eutteum , Lee Soo Young

The P2Y14 (purinergic receptor P2Y, G protein coupled, 14) receptor for UDP-glucose and other UDP-sugars has been implicated in the regulation of the stem cell compartment as well as neuroimmune function. However, the role of P2Y14 in osteoclast formation is completely unknown. We found that RANKL selectively induced P2Y14 among seven mammalian P2Y receptors when analysed at both the mRNA and protein level, but inhibitors of the MAP pathway suppressed induction of P2Y14 protei...

ba0003pp298 | Osteoporosis: treatment | ECTS2014

Investigating effects of novel conjugate drugs for the treatment of osteoporosis

Hu Sally , Willet Tom , Young Robert N , Grynpas Marc

Introduction: Prostaglandin E2 has bone-anabolic effects through EP4 receptor but its clinical utility is hindered by gastrointestinal side effects. To avoid these side effects, EP4 agonists (EP4a) were covalently linked to the bisphosphonate alendronate (ALN) to create two ALN-EP4a conjugate drugs, C1 and C2. When administered systemically, C1 and C2 will be target delivered to bone through ALN, where local hydrolytic enzymes liberate EP4a from ALN to exert bone an...